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Abstract
Sub-Saharan Africa (SSA), occupying about 80% of the African continent 
is a heterogeneous region with estimated population of 1.1 billion people in  
47 countries. Most belong to the low resource countries (LRCs). The high  prevalence 
of end-organ diseases of kidney, liver, lung and heart makes provision of organ 
donation and transplantation necessary. Although kidney and heart transplanta-
tions were performed in South Africa in the 1960s, transplant activity in SSA lags 
behind the developed world. Peculiar challenges militating against successful 
development of transplant programmes include high cost of treatment, low GDP 
of most countries, inadequate infrastructural and institutional support, absence 
of subsidy, poor knowledge of the disease condition, poor accessibility to health-
care facilities, religious and trado-cultural practices. Many people in the region 
patronize alternative healthcare as first choice. Opportunities that if harnessed may 
alter the unfavorable landscape are: implementation of the 2007 WHO Regional 
Consultation recommendations for establishment of national legal framework and 
self-sufficient organ donation/transplantation in each country and adoption of 
their 2020 proposed actions for organ/transplantation for member states, national 
registries with sharing of data with GODT, prevention of transplant commercializa-
tion and tourism. Additionally, adapting some aspects of proven successful models 
in LRCs will improve transplantation programmes in SSA.
Keywords: opportunities, challenges, low resource countries, end organ  
diseases/failure, transplant models
1. Introduction and overview
1.1 Background
Many diseases especially non-communicable diseases (NCDs) culminate in 
end-stage organ failures; the preferred treatment for most end-stage organ diseases 
is transplantation. Transplantation programme is a complex healthcare service 
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which entails huge costs and requires highly skilled health professionals, complex 
infrastructure and equipment, and well-articulated legal frameworks to enable its 
operationalization [1]. The need for appropriate interventions for organ failures 
in sub-Saharan Africa (SSA) is underscored by the high prevalence of end-organ 
diseases such as chronic kidney disease (CKD), chronic liver disease (CLD), chronic 
lung and heart diseases (interstitial lung disease, cystic fibrosis, cardiomyopathies 
and chronic rheumatic heart diseases) which cause increased morbidity and 
mortality. For example, Kaze et al [2] in a systematic review of prevalence studies 
on CKD in SSA documented the highest prevalence in West Africa 19.8%, Central 
Africa 16%, East Africa 14.4%, and Southern Africa 10.4%.
Globally, beside organs, tissues and cells (bone marrow cornea, etc.) are also 
transplanted. However, in SSA, apart from South Africa which also does liver and 
heart transplantation, the common organ transplanted is the kidney [3]. Though 
outcomes for transplantation have improved over the years due to better surgical 
techniques including minimal access surgeries, newer and better immunosup-
pressive medications, innovations in organ donation; improvement in transplant 
services is not apparent in SSA. Organ transplantation remains largely inaccessible 
and unaffordable to this population.
Sub-Saharan Africa has a disproportionate burden of communicable diseases 
(CDs) and NCDs compared to other world regions [4]. Currently, NCDs are respon-
sible for a large and increasing burden of death and disability in the region. World 
Health Organization (WHO) in 2018, documented that NCDs killed 41 million 
people per year accounting for 71% of the global deaths [5]. The ages most affected 
were 30 to 69 years age-group, belonging to the productive workforce of any popula-
tion. People from low income countries (LICs) and lower-middle income countries 
(LMICs) accounted for most of these deaths approximating over 85%. Four of the 
five commonly quoted diseases i.e. the “Big Five” (cardiovascular diseases, cancers, 
respiratory diseases, diabetes mellitus (DM) and mental illness) that account for 
most NCD deaths are drivers of CKD. Several risk factors with multiplier effect on 
NCDs are tobacco use, physical inactivity, harmful use of alcohol and unhealthy 
diets. Communicable diseases, though less common in high income countries 
(HICs) and upper-middle income countries (UMICs) are still prevalent in LICs 
and LMICs prompting WHO to highlight the double burden of diseases in these 
regions [6]. Both CDs and NCDs culminate in end-organ disease underscoring the 
high prevalence of end-organ failures, disabilities and deaths in SSA (see Figure 1). 
Unfortunately, most countries in this region lack resources to cope.
1.2 Prevalence of end-organ diseases
1.2.1 End-stage kidney disease (ESKD)
In 2014, Stanifer et al [7], in a systematic review and meta-analysis of 21 studies 
in SSA documented an overall CKD prevalence of 13·9%. According to the Institute 
for Health Metrics and Evaluation (IHME) data, CKD and DM were the 14th cause 
of death in SSA in 1990 but worsened to 11th by 2017 (see Figure 1). Hypertension 
and DM constitute the main NCDs that cause CKD globally [8]. In many low 
resource countries (LRCs), chronic glomerulonephritis and interstitial nephritis 
assume significance because of the pervading and persisting high prevalence of CDs 
(mainly bacterial, parasitic, and viral infections) [9]. Human Immunodeficiency 
virus (HIV) infection which continues to plague SSA, albeit better controlled, 
is a key driver of kidney disease. Of the 38 million people living with HIV glob-
ally, more than 25 million live in this region [10, 11]. The recent pandemic of 
COVID-19 infection which has adverse acute effects on the kidney has probable 
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unknown long-term sequelae [12]. Both CDs and NCDs fuel the high and increasing 
prevalence of CKD in LRCs. Without renal registries in many LRCs, there is poor 
 documentation of data on kidney diseases.
1.2.2 Other end-organ diseases
Viral hepatitis is prevalent in Africa with high endemicity of Hepatitis B Virus 
(HBV) in SSA and Hepatitis C virus (HCV) in North Africa. Africa has approxi-
mately 60–100 million of the world’s 257 million viral hepatitis infections [13]. The 
WHO noted that between 1980 and 2010, cirrhosis-related deaths doubled in the 
region. The increasing burden of obesity and DM leading to non-alcoholic fatty 
liver disease contributes to high prevalence of CLD and end-stage liver disease 
(ESLD). Up to 40% of patients with chronic hepatitis may progress to liver cirrhosis 
and/or liver cancer [14] and without liver transplantation mortality is estimated 
at about 15% in one year [15]. All patients with ESLD will invariably require liver 
transplantation; however, liver transplants are uncommon in SSA.
There is scant information on prevalence of other end organ failures such as 
heart, lung, and small bowel requiring organ transplantation in SSA.
1.3 Prevalence of transplantation
The WHO in collaboration with the Organización Nacional de Trasplantes 
of Spain set up the Global Observatory on Donation and Transplantation 
(GODT) with the mandate to document the distribution of organ transplantation 
Figure 1. 
Causes of deaths in sub Saharan Afirca 1990 and 2017 [from Institute for Health Metrics and Evaluation 
(IHME) data].
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programmes in the countries that report their data to the Observatory and to evalu-
ate the access of transplantation activities worldwide [16]. Upon subsequent request 
of the World Health Assembly (Resolutions WHA57.18 and 63.22) that global data 
on the practices, safety, quality, efficacy, epidemiology and ethical issues of allo-
geneic transplantation be collected and documented, the GODT was inaugurated 
in 2007 [16]. This database has ensured provision of transparent and equitable 
monitoring of national transplant systems.
Currently, according to the GODT database, [17], 139,024 solid organ trans-
plants were reported globally in 2017: 90,306 kidney (36% from living donors), 
32,348 liver (19.0% from living donors), 7881 heart, 6084 lung, 2243 pancreas 
and 162 small bowel transplants. Africa contributes the least number of trans-
plant activity per continent and SSA the least number per WHO World region 
(Tables 1 and 2; Figure 2). Tables 1 and 2 show data from 2016 GODT Report.
Kidney transplants are available in 102 countries; living kidney transplants in 98 
countries and deceased donors in 76 countries [16]. Sixteen countries representing 
6.6% of the global population perform only living donor kidney transplants. In SSA, 
a handful of countries carry out transplantation: South Africa, Sudan, Seychelles, 
Ivory Coast, Namibia, Nigeria, Kenya, Ghana, Tanzania, Mauritius, Ethiopia 
but only five countries (Ethiopia (0.34 pmp), Kenya (1.51 pmp), Nigeria (0.47 
pmp), South Africa (6.81 pmp) and Sudan (6.58 pmp)) report their data to GODT 
(Figure 2).
1.4 Characteristics of SSA
1.4.1 Geography and demography
Sub-Saharan Africa is heterogeneous and has a population estimated at 1.1billion 
[18]. It is projected that countries in this region would account for more than half of 
the world’s growth by 2050 [19]. This geographical region fully or partially located 
south of the Sahara Desert occupies an area of about 24 million Km2 (Figure 3). It 
is made up of 47 countries divided into 4 WHO sub-regions. Most countries in this 
region belong to the LICs and LMICs according to World Bank Classification of 
economies and are also described as LRCs. Africa is the second largest and second 
most populous continent; SSA occupies about 80% of the continent [20]. Although 
the economic growth in Africa has been remarkable in recent years, the gap between 
the rich and poor is wide and many people still do not have access to basic amenities 









AFR 46 10 (21.7) 1139.1 506.6 (44.5)
AMR 35 21 (60.0) 986.5 968.5 (98.2)
EMR 22 15 (68.2) 656.1 535 (81.5)
EUR 53 49 (92.5) 909.7 904.2 (99.4)
SEAR 11 5 (45.5) 1928.4 1408.8 (73.1)
WPR 27 11 (40.7) 1847.7 1815.3 (98.3)
Total 194 111 (57.2) 7467.5 6138.4 (82.2)
Table 1. 
Proportion of countries and population covered by the GODT database in the WHO regions. Year 2015 [17].
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1.4.2 Dynamics of healthcare
1.4.2.1 Health systems
The WHO defines health systems as “all organizations, people and actions whose 
primary intent is to promote, restore, or maintain health” [21]. In LRCs, these 
systems have long been weak and deficient in most aspects of healthcare delivery 
and therefore, there is persistent need to evaluate health system challenges at all 
levels [22]. Health security is a crucial public health issue. It is ensured when there 
is protection against any health threats and also involves ability to handle emerging 
new health conditions by adapting and developing new approaches [23]. The epi-
demics in recent years (SARS, MERS and Ebola) including the COVID-19 pandemic 
bring to the fore the inability of the health systems in SSA to cope with health crisis 
and other prevalent health conditions [24].
1.4.2.2 Personnel
Some healthcare professionals have poor work ethics deriving from unsavory 
work environment and remunerations. Transplantation is a highly specialized ser-
vice that entails full commitment of the workforce and long work hours. For a good 
transplant programme, the national health system and the hospitals have to commit 
to improving the skill set of the work force through adequate staff training and 
other development opportunities, incentivization of the programme and offering a 
very supportive work environment [25].
1.4.2.3 Health seeking behaviour
Traditions and cultures influence the mindset of a people; decision to access 
healthcare service is informed by many factors (accessibility, affordability, 
spirituality and religiosity, and knowledge of the disease condition) [26]. When 
ill, many people in LRCs seek alternative healthcare service including traditional 





















Kidney 488 (1.0) 31,859 (32.9) 6127 (11.5) 26,131 (28.9) 7202 (5.1) 12,540 (6.9)
Liver 67 (0.1) 10,426 (10.8) 1539 (2.9) 9582 (10.6) 1292 (0.9) 4853 (2.7)
Heart 14 (0.03) 3604 (3.7) 135 (0.3) 2646 (2.9) 40 (0.03) 584 (0.3)
Lung 12 (0.02) 2507 (2.6) 56 (0.1) 2007 (2.2) 1 (0.0) 463 (0.3)
Pancreas 5 (0.01) 1236 (1.3) 24 (0.04) 890 (1.0) 1 (0.0) 143 (0.1)
Small 
Bowel
0 (0.0) 147 (0.2) 4 (0.01) 43 (0.05) 0 (0.0) 1 (0.0)
Total 
Organs
586 (1.2) 49,779 (51.4) 7885 (14.7) 41,299 (45.7) 8536 (6.1) 18,585 (10.2)
Table 2. 
Absolute numbers and rates of the organ transplant activities per WHO region. 2015 [17].
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1.4.3 Health financing
In 2018 and 2019, Africa’s economic growth was at 3.4% and was expected to rise 
to 3.9% and 4.1% in 2020 and 2021 respectively [28]. Amid the COVID-19 pandemic 
of 2020, the dynamics changed resulting in contraction of economies globally with 
expected 1.7% to 3.4% contraction of Africa’s economy [29].
The 2001 Abuja Declaration recommended allocation of 15% of the annual 
national budget to the health sector; achieving this has been challenging [30]. 
In 2012, 6 countries met the target; and this reduced to 4 in 2014. Currently, the 
preferred indicator for health financing is the percentage gross domestic product 
(% GDP). To achieve universal health coverage (UHC), the World Health 2010 
Report suggested that a national government has to spend at least 4–5% of GDP on 
Figure 2. 
World map of transplantation in 2019 showing total sum of transplants [from global Observatory of Donation 
and Transplantation].
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health [31]. Whilst per capita expenditure on health in America and Europe were 
over $1800 in 2014, the per capita expenditure on health in Africa averaged only 
$51.6 [32]. Further analysis shows that over the same period, in Africa, general 
government health expenditure was less than 50% of the total health expenditure 
while other sources such as out of pocket (OOP) payments and external sources 
(from funders) accounted for over 50% [32]. In general, transplantation service 
largely depends on robust and adequate finances hence the programme thrives in 
HICs and UMICs.
1.5 History of transplantation
1.5.1 Southern Africa
South Africa: the first organ transplantation in Africa was kidney transplant 
performed by Thomas Starlz and colleagues in 1966 at Wills Donald Gordon 
Medical Centre, Johannesburg, South Africa [33]. This was followed in 1967 by the 
first successful heart transplant performed in the world at Groote Shuur Hospital, 
Cape Town, South Africa by Christian Barnard [34, 35]. Barnard and his team 
championed the orthotopic and heterotopic (‘piggy-back’) heart transplant. From 
1968 to 1983, they engaged in research on cardiac transplantation thereby laying the 
foundation for heart transplantation as therapy for end-stage cardiac disease. The 
team advanced the concept of brain death, organ and tissue donation, and ethical 
issues in transplantation. They also researched on methods to improve preservation 
Figure 3. 
Map of Africa showing UN sub-regions.
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and protection of the donor heart: their studies ranged from developing appropriate 
hypothermic perfusion for heart storage, haemodynamics and metabolic changes in 
brain death to xenotransplantation [34].
Though, South Africa has the most advanced transplant programme in the con-
tinent, globally, their transplant activities remain lower than those of other coun-
tries with comparable economic capacity [35, 36]. South African liver programme 
has existed for about 2 decades and presently offers living-related liver transplanta-
tion. Other solid organ programmes available are combined kidney-pancreas and 
lung transplantation. Her donor programmes have advanced to extended criteria 
donors (ECD) and donors after circulatory death [37]. South Africa has high preva-
lence of HIV resulting in a huge HIV-positive population prompting Muller and 
colleagues to pioneer HIV-positive-to-positive transplant program in 2008 [38]. By 
2018, this programme had successfully transplanted 43 kidneys from 25 deceased 
donors [39].
Namibia had first kidney transplantation in March 2016 [40] and is also 
reported to have done a heart transplant [41].
1.5.2 West Africa
Ghana started a kidney transplant programme in 2008 at Korle Bu Teaching 
Hospital, Accra in collaboration with a hospital and a charity organization in UK. 
Between 2008 and 2014, the programme performed 17 transplants and in 2015, they 
established a national registry [42].
Ivory Coast implemented the law authorizing organ donation in 2012 [43] 
and between 2013 and 2015, ten living-related kidney transplantations had been 
done [44].
Nigeria commenced organ transplantation activity in 2000 in a privately-
owned hospital [45]. Currently, there are 15 centres (public 9, private 6) and 
over 770 transplants had been performed between 2000 and 2019 [Personal 
Communication].
1.5.3 East Africa
Ethiopia commenced its transplant programme in collaboration with an 
American hospital in September 2015 and by February 2018, had done 70 living 
donor kidney transplants at their only transplant centre [46].
Kenya started kidney transplantation in 2009 and by 2019 had performed 200 
transplants. Their government augmented the existing infrastructures to support 10 
transplants per month [47].
Mauritius began kidney transplantation in 1980 and discontinued in 1982 
following poor outcomes but resumed in 1993 [48]. Although the “Human Tissue 
(Removal, Preservation and Transplant) Act” was promulgated in 2006 and 
amended in 2013, a new legislation was enacted in 2018 [49].
Sudan, according to the African Union belongs to East African sub-region 
even though the United Nations categorized her as North Africa. Sudan had her 
first kidney transplant in 1974 and for the subsequent 25 years performed very few 
transplants. However, in 2000, the program was reactivated; and 222 transplants 
were performed in 2016 [50].
Tanzania started kidney transplantation services locally in collaboration with 
hospitals in India and Japan in November 2017 [51]. Earlier, her program consisted 
of government-sponsored transplantation overseas. Recipients and donors received 
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pre-transplantation work-up locally and donor verification by DNA profiling was 
done to curtail commercialization.
Ugandan cabinet in June 2020 approved a bill to establish a legal framework for 
human organs, cells and tissue transplant, and to regulate donations and trade in 
human organs, cells and tissue [52].
1.5.4 Central Africa
No country in this sub-region has a transplant programme but Angola in 
March 2019 passed a law on human tissue, cell and organ transplant to enable 
transplantation [53].
In SSA, the national programs for donation and transplantation of organs and 
tissues are slow and poorly developed and they are fraught with inadequacies 
in infrastructures, institutional support, and technical expertise [3]. These are 
attributed to the huge costs and complexity of transplantation, low GDP, lack of 
subsidy and dearth of facilities.
Loua et al in 2018, documented that 62 transplant centres across seven countries 
in Africa had transplant activities involving kidney, heart, cornea, liver and bone 
marrow [3].
1.5.5 Stratification of transplant programmes
Programmes are classified into different stages of development of transplant 
services with those from HICs better developed than those from LMICs and LICs 
[54] (See Table 3).
Stage Characteristic Country
I No existing transplant programme with little or no posttransplant and 
post-donation care. Transplant tourism is rife.
The poorest 
countries of the 
world
II Faltering or poorly developed transplant programme offering only 
living-related donation, no nationally structured transplant program, 
and often no legislation. There is nonexistent deceased-donor program 
and proliferation of transplant tourism with little or no posttransplant 
and post-donation care.
Countries in sub-
Saharan Africa and 
many other low- and 
middle-income 
countries
III Fairly developed transplant programme offering mostly living-
related donation with rudimentary deceased-donor program. Poorly 
developed kidney paired exchange and organ sharing programs, 
often with poor posttransplant and post-donation care. Some level of 
transplant tourism and moderate to long wait time.
Many countries in 
Asia, Central and 
South America, the 
Middle East, and 
North Africa
IV Well-developed structured transplant programme and accompanying 
legislation offering deceased donation, kidney paired exchange, and 
organ sharing programs with good posttransplant and post-donation 
care. Little transplant tourism and short to moderate wait times for 
transplant.
Many of the 
developed 
economies belong to 
this stage
V Highly developed and structured transplant programme and 
accompanying legislation offering mostly deceased donation, 
advanced donation/kidney paired exchange, and organ sharing 
programs with excellent posttransplant and post-donation care. There 
is no transplant tourism and short or no wait times for transplant.
Utopian
Table 3. 
Proposed staging for transplant stratification model (transplant transition) [54].
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2. Recipient and donor evaluation
2.1 Recipient
Careful evaluation of potential organ transplant recipients is necessary to detect 
co-existing illnesses that can adversely affect the prognosis of the transplantation. 
The subsisting clinical practice guidelines including the 2020 KDIGO guideline and 
the 2011 UK Renal Association Clinical Practice guideline (5th Edition) [55, 56] 
recommend the standard process of evaluation of prospective transplant recipients. 
Regardless of the recommendations of the practice guidelines, most transplant 
centres have their in-house protocols for transplant recipient evaluation. However, 
in SSA, the evaluation may be tailored to the available resources but should be 
efficient and cost-effective. The discussion below is typical for kidney transplant 
units in Nigeria but may apply to other organ transplantations and transplantations 
in other countries in the sub-region.
The evaluation of such candidates involves risk/benefit assessment and they 
should have at least five-year life expectancy derived from age, gender and race 
of the individual [57]. Many clinicians, however, consider other factors including 
severity of life-threatening diseases, functional status, clinical experience and 
knowledge of the patient to determine suitability for organ transplantation.
2.1.1 Workup for transplant candidates
The workup evaluation includes: hematological, clinical chemistry, infec-
tion profile, diagnostic procedures, imaging and immunological tests. The list of 
relevant investigations is shown in Table 4.
2.1.1.1 Hematological studies
Blood grouping establishes the candidate’s blood type and determines if further 
evaluation should proceed. Recipient and donor must be compatible. Complete 
blood count and clotting profile should be optimal.
2.1.1.2 Cardiac evaluation
All candidates are assessed for presence of cardiac disease by history, physical 
examination and electrocardiogram. Recipients with cardiac disease, comor-
bidities that predispose to coronary artery disease (CAD), history of previous 
CAD or poor cardiac function are further assessed by cardiologists. Generally, 
contraindications for transplantation include severe heart disease (New York 
Heart Association [NYHA] Functional Class III/IV), severe CAD, left ventricular 
dysfunction [ejection fraction <30%] and severe valvular disease.
2.1.1.3 Pulmonary evaluation
Chest radiograph is required for all candidates while chest computerized tomog-
raphy (CT) is reserved for current or former heavy smokers (≥ 30 pack-years). 
Candidates with lung disease are further evaluated by a pulmonologist. Severe 
irreversible obstructive or restrictive pulmonary diseases are contraindications for 
transplantation.
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2.1.1.4 Tuberculosis screening
Sub-Saharan Africa has high prevalence of tuberculosis (TB). It is therefore 
necessary to screen for TB in prospective organ recipients with a chest radiograph 
and purified protein derivative (PPD) skin test. Candidates with positive TB 
screening tests are treated before organ transplantation.
2.1.1.5 Gastrointestinal evaluation
Candidates with history of peptic ulcer disease (PUD) are screened with 
oesophagogastroscopy and Helicobacter pylori test. Active diseases including PUD, 
diverticulitis, pancreatitis, cholelithiasis and inflammatory bowel disease should be 
controlled before transplantation.
2.1.1.6 Serologies
Serological tests for potentially transmissible diseases, like HIV, HBV, HCV, 
cytomegalovirus (CMV), Epstein–Barr virus and varicella-zoster virus are usually 
performed, and appropriate management instituted when indicated.
Blood 1. Complete blood count and differential
2. Blood group
3. INR, PTT
4. Tissue typing: CDC and flow cytometry
5. Electrolytes: sodium, potassium, calcium, magnesium
6. Kidney function: urea, creatinine
7. Liver function: bilirubin, total protein, albumin, alkaline phosphatase, ALT, 
AST, LDH, GGT
8. Fasting blood glucose, glycated hemoglobin
9. Total cholesterol, HDL, LDL, VLDL, TG
10. Serology: HIV, HBsAg, Anti HCV, CMV, syphilis, EBV, HSV
Radiology 1. Chest radiograph




Immunology 1. HLA typing, HLA antibodies, crossmatching
Gynecological 1. Pap smear, mammogram for women >40 years or family history of breast 
cancer
Other tests 1. Electrocardiogram
2. Echocardiography
3. Colonoscopy if >50 years
4. PSA in men >50 years
Table 4. 
Workup for prospective organ transplant recipients.
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2.1.1.7 Cancer screening
Routine cancer screening is done for all recipients. Chest radiograph is 
mandatory while chest CT is reserved for current or former heavy smokers. 
Ultrasonography is used for screening candidates at risk of renal cell carcinoma 
(dialysis >3 years, family history of renal cancer, acquired cystic disease, analgesic 
nephropathy). Those at risk of urinary bladder cancer (high-level exposure to 
cyclophosphamide, heavy smoking) require cystoscopy. Patients at risk of hepato-
cellular carcinoma are screened with ultrasonography and serum alpha fetoprotein. 
Colonoscopy is done to screen for bowel cancer and inflammatory bowel disease. 
Females undergo PAP smear and mammography to exclude cervical and breast 
cancer respectively.
2.1.2 Obesity
Obesity increases the risk of post-operative complications. Many transplant 
centres prefer a body mass index (BMI) of <30.
2.1.3 Financial considerations and psychosocial status
These are very important aspects of the workup for prospective organ transplant 
recipients and will be discussed later.
2.2 Donor
Donor protection should always be taken into account during living donor 
selection and assessment. Organ donation should be altruistic, voluntary and 
never coerced. Donor evaluation is a multidisciplinary exercise, and is done before, 
during and after donation. Due to lack of requisite legislation, supporting infra-
structure, religious and cultural beliefs, mostly living organ donations are done in 
SSA countries.
There are risks associated with organ donation and consequently, potential 
donors should receive medical, surgical and psychological screening. Pre, intra, and 
post-operative care as well as structured post-donation follow up are important.
2.2.1 Clinical evaluation
Potential donors should be healthy and neither too young nor too old. Medical 
history and physical examination could elicit risk factors for kidney disease such 
as: DM, hypertension, family history of kidney disease, herbal drug, non-steriodal 
anti-inflammatory drugs (NSAIDs), and other nephrotoxin use. History and/or 
presence of CLD could be suggested by jaundice and alcohol abuse. Also, history 
of psychiatric illness, malignancies, smoking and substance abuse, etc. should be 
sought and positive candidates excluded. Donors should not be morbidly obese and 
blood pressures should be <140/90 mmHg.
2.2.1.1 Donor work-up
For various investigations see Table 5.
Absence of urinary markers of disease such as proteinuria, haematuria, pyuria 
and casts, may rule out kidney diseases in potential donors. Glomerular filtration 
rate (GFR) should ideally be measured but is often estimated using serum cre-
atinine in most LRCs. Prospective donors are screened for chronic viral diseases. 
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Notably, CMV positivity in a donor has implication for a CMV-negative recipient, 
who due to subsequent immunosuppressive drug use will likely succumb to its 
infection. Screening for TB (CXR, Mantoux test, sputum GeneXpert) is important 
in SSA because 1/3 of the population is infected with M. tuberculosis [58]. The ABO 
blood group compatibility with recipient is mandatory; however, Rhesus factor 
mismatch is not a major consideration for solid organ matching. There are many 
HLA antigens (Class I: HLA-A, B, and C; Class II: HLA-DR, DQ and DP), but the 
HLA A, B and DR are usually cross-matched between donors and recipients (i.e. 
tissue typing).HLA antibody cross-matching is important to prevent early graft 
rejection. It detects the presence of HLA antibodies in recipients that can react with 
donor’s lymphocytes, i.e. donor specific antibodies (DSA).
HLA antibody cross-matching was originally based on complement dependent 
cytotoxicity (CDC) assays. It is done with recipient’s serum on donor lymphocytes 
or pooled lymphocytes of previous donors within the transplant centre’s population 
to determine the Panel Reactive Antibodies (PRA). Reactive Antibodies (PRA). The 
PRA estimates the recipient’s chances of tolerating allografts from that population 
and is useful for deceased donation.
Solid phase assays, ELISA or flow cytometry (Luminex)-based are now avail-
able and preferred. Most transplant centres in SSA, outsource tissue typing and 
HLA antibody cross-matching. Protocols require at least two HLA antibody cross-
matches, with the last, just before the transplant procedure.
Imaging evaluation using ultrasonography and doppler in prospective donors 
should demonstrate normal kidneys (sizes and echotexture) and renal blood flow.
The CT-angiography helps to rule out solitary kidney or detect the presence of 
multiple or abnormal renal arteries, which have surgical implications for nephrec-
tomy in donors and anastomoses in recipients.
2.2.2 Counseling
Counseling donors on short and long-term risks associated with organ dona-
tion is necessary. Possible complications such as pain, post-operative infections, 
blood loss, deep venous thrombosis and pulmonary embolism can occur. Studies 
have shown that peri-operative mortality and morbidity during organ donation, 
Parameters Relevant indices
Age >18, <60 years
History Diabetes mellitus, hypertension, nephrotoxins, alcohol and other substance 
abuse, cigarette smoking, psychiatric illness, malignancy
Physical features Jaundice, pallor, BP >140/90 mmHg, BMI >35
Laboratory features
Hematological FBC, PT/INR
Chemistry SEUCr, LFT, lipid profile, FBG, HBA1C, PSA, TFT
Microbiology Urinalysis, urine culture
Serological/ 
immunological
HIV, Anti HCV, HBsAg, CMV, EBV, ABO blood group, HLA A, B and DR 
matching, HLA antibody cross- matching
Imaging Ultrasound, CT angiography,
Others ECG, Echocardiography
Table 5. 
Workup for potential organ transplant donors.
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are about 0.03% and 10% respectively [59]. Some studies show that with careful 
selection, kidney donors live long, although hypertension, proteinuria and reduced 
GFR can occur over time [60]. The risk of ESKD following kidney donation is about 
0.3% [61]. Emotional consequences after organ donation should be anticipated 
therefore psychosocial assessment should be independently organized by the 
transplant team before and after donation.
2.3 Post donation follow-up
Many transplantation programmes in SSA adopt protocols from established and 
experienced centres.
According to US Organ Procurement and Transplantation Network (OPTN) 
guidelines, living donor follow-up is done at discharge (or at 6 weeks), 1 year and 
2 years [62]. Parameters monitored include weight, blood pressure, lipid profile, 
kidney and liver functions. Healthy eating, regular exercise and the dangers of 
substance abuse are emphasized. After uneventful 2 years, donor follow-up is 
continued by the primary care physicians but for those with adverse outcomes 
appropriate referral is made. Post-donation follow-up is important for donor safety 
and wellbeing to enable diagnosis and treatment of co-morbidities.
2.4 Psychosocial evaluation
In transplantation, recipients, donors and their families are faced with various 
challenges including psychological and behavioral issues. Evaluation is essential in 
the following aspects: candidate and donor selection, counseling, pre- and post-
transplant assessment, patient, caregiver and family adjustments to transplant and 
issues related to psyche of transplant staff.
2.4.1 Recipient
Various factors exert neuropsychiatric effects in transplantation. Studies link 
significant neuropsychiatric adverse effects to cyclosporine, tacrolimus, steroids 
and other components of treatment. Therefore, psychosocial issues should be 
considered and addressed in order to achieve a successful transplant.
Psychosocial evaluation of patients for transplant include [63]:
• Patient profile: relationships, education, work and legal history
• Expectations from the surgery
• Organ failure: cause, complications, course, adherence to treatment
• Ways of coping with the illness
• Support network: caregivers, family, friends, faith organizations and 
employers
• Psychiatric history: extant, past and family.
• Substance abuse history
• Mental status exam: neuropsychiatric tests
• Ability to give informed consent
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There are known stressors before and after transplantation including depression 
and hopelessness, anxiety, uncertainty and aggression. These may be followed by 
hope, and confidence in an unpredictable pattern as recipients gradually process 
adaptation to the new situation.
After Transplantation, recipients pass through three phases of adaptation [64]:
• “Foreign body” phase: the organ feels strange to the recipient. Persecution 
anxiety or idealization could arise. The organ could be seen as fragile and 
 precious, thereby generating excessive protective feelings towards it.
• “Partial incorporation” phase: recipient begins to integrate the organ.
• “Total incorporation” phase: recipient is no longer aware of the organ.
In the long-term postoperative period, medication side effects and associated 
comorbidities become central stressors affecting the recipients’ quality of life 
(QOL). The most bothersome stressors are work related, like farming, schooling, 
etc. [65]. Recipients might feel stressed by the strict adherence to the medical regi-
men. This, in turn, can compromise their adherence after transplantation. Financial 
problems and legal disputes constitute other possible sources of psychological strain 
with health or pension insurance agencies, where available.
Enabling transplant recipients commence productive employment constitutes 
the main goal of transplantation and is considered an indicator of societal participa-
tion [66]. Globally, data show that 18% - 86% of recipients return to work or find 
new employment. [67, 68] but no data is available for SSA.
2.4.2 Donor
2.4.2.1 Donors’ motives and decision-making
Multiple factors motivating donors include intrinsic factors (e.g., desire to 
relieve another’s suffering or to act in accordance with religious convictions) and 
extrinsic factors (social pressures or perceived norms) that may operate simultane-
ously. The combination of motivational forces differs depending on whether and 
how the donor is related to the recipient.
Most living donors use two decision-making strategies: [69]: “moral” which 
involves awareness that one’s actions can affect another [70] and “rational” which 
is focused on gathering relevant information, evaluating alternatives, selecting an 
alternative, and implementing the decision.
2.4.2.2 Psychological status and post-donation psychosocial outcomes
Potential donors’ psychological stability has been one of the greatest concerns 
for living transplant programmes, particularly in the context of unrelated donation. 
The willingness or desire to donate to a stranger has been historically viewed with 
suspicion [71, 72]. Studies suggest that most potential donors do not suffer from 
mental illness [73, 74]. Many donors have reported positive feelings about dona-
tion however, a few have observed psychological distress, anxiety and depression. 
Thus, it becomes critical to identify, and mitigate key risk factors for these poorer 
outcomes: non-first degree relatives [75, 76], ambivalent donors [76, 77] and “black 
sheep” donors (persons who donate in order to compensate for past wrong doings 
or to restore their position in the family) are at higher risk for poorer post-donation 
psychosocial outcomes [76, 77].
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3. Surgical aspect of transplantation
3.1 Donor surgery
The donor kidney angiogram is decisive in selecting the kidney to be harvested. 
The larger kidney with better blood flow is left for the donor. Minimal access donor 
nephrectomy and robot-assisted renal engraftment reduce postoperative complica-
tions. These, however, are not easily available in most LRCs.
3.1.1 Complications of donor nephrectomy
Post-operative donor complications occur in 7.9–22% with bleeding in about 3%. 
Infectious, gastrointestinal, respiratory, cardiac and psychiatric complications may 
occur [78–80].
3.2 Recipient surgery
The harvested kidney is covered in ice slush, wrapped in gauze piece and 
preserved in ice container as organ perfusion machine is not readily available in the 
sub-region.
Kidneys with multiple arteries are avoided but if inevitable, arteries are 
 anastomosed side to side, end to side, or separately onto the external iliac artery  
(Figure 4). The right external iliac vessels are more superficial than the left and this 
side is frequently preferred for the first renal engraftment.
Anti-reflux uretero-cystostomy is performed over a size 4Fg double J-ureteric 
stent (Figure 5).
3.2.1 Pitfall in recipients surgery
Sclerosed External Iliac Vein (EIV): this results from repeated cannulation 
of EIV for hemodialysis. Recipient pre-operative EIV doppler ultrasound scan for 
patency is important. Major complications of recipient engraftment include bleed-
ing, delayed graft function, hyperacute rejection and allograft renal vein thrombosis.
3.3 Peri and post-operative care of renal transplant recipient
Immunosuppressive regimen is divided into induction and maintenance phases.
3.3.1 Induction phase
This is required to prevent acute rejection. Due to sensitization from blood 
transfusions, previous pregnancies (females) and increased susceptibility to graft 
rejection (in blacks) recipients undergo induction [81]. A combination of anti- 
thymocyte globulin (ATG) and methylprednisolone is often used. Prior to this, 
patients receive pretreatment with acetaminophen and antihistamines to prevent 
cytokine release syndrome associated with ATG.
Biologic agents (Alemtuzumab, Basiliximab, Daclizumab) may be used when 
available in less sensitized patients.
3.3.2 Maintenance regimen
To prevent allograft rejection, maintenance immunosuppression is achieved 
with a combination of low dose corticosteroid (prednisolone is widely in available 
SSA), an antiproliferative agent (mycophenolate mofetil (MMF) or azathioprine) 
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and a calcineurin inhibitor (CNI) (tacrolimus (TAC) or cyclosporine (CYP)). 
Tacrolimus has shown superiority over cyclosporine in improving graft survival and 
preventing acute rejection. Thus, TAC remains an integral part of the common post- 
transplant immunosuppressive combination [82]. The initiating dose is titrated to 
achieve a trough level of 8-10 ng/ml in the first three months post-transplant.
Prophylaxis against bacteria, fungi and viruses are commenced within this time.
Figure 4. 
Donor angiogram with multiple left renal arteries.
Figure 5. 
End-to-side donor-recipient arterial anastomosis with kidney wrapped in gauze piece packed with saline ice slush.
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3.3.2.1 First post-operative week
First day post-surgery, emphasis is on haemodynamic and respiratory stability 
as well as urine output. By the first week, good graft function should have been 
established and urethral catheter is removed.
3.3.2.2 First three post-operative months
Within this period opportunistic infections are anticipated and appropriate 
measures taken. The ureteric stent is removed within 4 – 6 weeks.
3.4 Transplant outcomes in SSA
Absence of transplant registries in SSA precludes transplant data availability. 
However, between 2010 and 2015, a hospital in South Africa documented recipi-
ent survival at 1 and 5 years as 90.4% and 83.1% and that of graft 89.4% and 80% 
respectively [83].
4. Challenges of transplantation
Organ donation and transplantation in SSA is fraught with numerous challenges 
including costs of treatment, inadequate infrastructure and equipment, dearth of 
highly skilled health professionals, and lack of well-articulated ethico-legal frame-
work and policies [3].
4.1 Cost of treatment
Cost of kidney transplant varies from country to country. For example, the cost 
is estimated at about $32,000 in Nigeria [84], $18,775 in Ghana [85], and $10,000 
in Tanzania [20].
Source of funding for organ and tissue donation and transplant depends on 
the country: public sources in Ethiopia, Ghana, Mali, Seychelles and Comoros but 
private in Nigeria, Burkina Faso, Madagascar and 10 other countries See Table 6. 
Most recipients pay OOP either personally or by relatives, employers and to a lesser 
extent philanthropists [45]. While the National insurance pays two-thirds of the 
transplant cost in Kenya [47], it is free in Tanzania [51].
Post-transplant maintenance of immunosuppression is a major challenge. This 
is exigent since therapy must be individualized. Two perspectives associated with 
immunosuppression in SSA include:
• Availability, affordability and patient’s adherence to prescription.
• Therapeutic drug monitoring (TDM).
4.1.1 Availability, affordability and patient’s adherence to prescription
Adequate immunosuppression is key to allograft survival. In patients who pay 
OOP, prohibitive costs of medications may have negative impact on their finances. 
Furthermore, side effects of medications affect their health-related QOL. In many 
LRCs, these medicines are imported at high cost and not readily available. These 
contribute to poor adherence with subsequent allograft rejection and graft loss.
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Indicator Countries
Countries with functional transplantation programmes
Functional transplantation programmes from 
living donors
Algeria, Côte d’Ivoire, Ethiopia, Ghana, Kenya, 
Namibia, Nigeria, United Republic of Tanzania, 
Uganda, South Africa
No. of transplant centres in the region
Kidney centres Algeria, Côte d’Ivoire, Ethiopia, Ghana, Kenya, 
Namibia, Nigeria, United Republic of Tanzania, Uganda
Corneal centres Kenya, Nigeria, South Africa
Bone marrow centres Nigeria, South Africa
Liver centres South Africa
Heart centres South Africa, others perform open heart surgeries
Countries having legal requirements
Legal requirements in place covering organ 
donations and/or transplantations
Burkina Faso, Comoros, Côte d’Ivoire, Ethiopia, Kenya, 
Mauritius, Namibia, Nigeria, Rwanda, Senegal, Sudan, 
United Republic of Tanzania, Uganda, Zimbabwe
Governments intended to adopt new legal 
requirements
Cameroon, Chad, Eswatini, Ghana, Guinea, 
Madagascar, Mali, Mozambique
No legislations in place Angola, Benin, Burundi, Cabo Verde, Congo, Eritrea, 
Gabon, Guinea Bissau, Seychelles, Sierra Leone
Legal requirements in place to inform living 
donors on the risks of the operation
Comoros, Ethiopia, Kenya, Mali, Nigeria, Rwanda, 
Senegal, Seychelles, United Republic of Tanzania, 
Uganda
Legal restrictions on the coverage of donation 
costs for living donors
Comoros, Mali, Rwanda, Senegal
Legal requirement to follow-up on the outcomes 
of living donors
Ethiopia, Mali, Senegal, Seychelles
Legal requirement to provide care to 
living donors in case of adverse or medical 
consequences
Ethiopia, Senegal, Seychelles
Prohibition of organ trafficking/transplant 
commercialization
Burkina Faso, Comoros, Côte d’Ivoire, Mali, Namibia, 
Nigeria, Rwanda, Senegal
Legal permit and regulation of financial 
incentives for living donors
None
Import or export of organs authorized Ghana, Namibia, Rwanda
Import or export of organs explicitly prohibited Burkina Faso, Seychelles
Legal requirements for organ and tissue 
donations from living donorsa
Burkina Faso, Comoros, Côte d’Ivoire, Kenya, Mali, 
Nigeria, Rwanda, Senegal, Seychelles, United Republic 
of Tanzania, Uganda
No. of countries having an organization and management system
Authorization for transplant services Burkina Faso, Comoros, Côte d’Ivoire, Ethiopia, Ghana, 
Guinea, Kenya, Madagascar, Mali, Nigeria, Senegal, 
Uganda, Zimbabwe
Ethics Committees at the national or local level Burkina Faso, Comoros, Côte d’Ivoire, Ethiopia, Gabon, 
Kenya, Mali, Nigeria, Rwanda, Senegal
Government recognized authority at the 
national level
Algeria, Côte d’Ivoire, Ethiopia, Ghana, Kenya, Mali, 
Nigeria, Senegal, Uganda
Setting up protocols, guidelines, 
recommendations
Comoros, Côte d’Ivoire, Ethiopia, Mali, Senegal
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4.2 Therapeutic drug monitoring (TDM)
Despite their impactful role in improving transplant outcome and graft survival, 
immunosuppressive medicines exhibit narrow therapeutic range between levels 
that inhibit rejection and toxic levels hence TDM is often required. Establishing a 
patient’s dose requirements in the immediate post – surgery period and avoiding 
over immunosuppression remains a challenge. Calcineurin inhibitors have variable 
pharmacokinetics [86–89]. While ethnic differences have not been demonstrated in 
pharmacokinetics of MMF and AZA, African Americans have been shown to have 
20–50% lower oral bioavailability for TAC, CYP, sirolimus and everolimus and as 
such require higher drug doses than Caucasians [90, 91]. This has been attributed to 
genetic polymorphism of key enzymes in the metabolism of these medications [90]. 
Genetic profiling is not readily done in SSA hence, TDM is essential. This attracts 
huge costs for the health system and for patients who pay OOP. It is imperative to 
tailor medications to patient’s need. Some countries do not have the capacity to ana-
lyze drug levels, so patient’s blood samples are sent overseas for analysis. Within the 
first-year post-transplant, TDM is done at least twice during timed follow-up visit 
for patients coming from rural and urban areas. However, more frequent monitor-
ing is done when indicated. During emergency presentation for allograft dysfunc-
tion, patients are admitted, samples for TDM sent out and other possible causes of 
allograft dysfunction are excluded or managed if present. Decision to increase drug 
dosage is often delayed till TDM result is available but dose reduction or withdrawal 
can be done in the presence of overt signs and symptoms suggestive of toxicity. For 
subsequent years, TDM is done as indicated.
4.3 Lack of infrastructure and equipment
Tissue typing, cross-matching and some viral studies, which are major aspects of 
patient preparation, are done overseas. This tends to delay the procedure and leads 
to an increase in the cost of transplantation. Adequate histological evaluation of 
biopsy specimens are largely unavailable, making prompt management of rejections 
and infections problematic.
Indicator Countries
Transplant follow-up registries for post-
transplant living donor and for recipients
Côte d’Ivoire, Ethiopia, Namibia, Uganda
Affiliation with an international organ 
allocation organization
None
Cooperation framework to allow 
transplantation abroad
Côte d’Ivoire, Ethiopia, Kenya, Namibia, United 
Republic of Tanzania, Uganda
Training programme for staff in place Côte d’Ivoire, Ethiopia
Source of funding
Public Comoros, Ethiopia, Ghana, Mali, Seychelles, United 
Republic of Tanzania
Private Côte d’Ivoire, Ghana, Nigeria
Public and Private Kenya, Namibia, South Africa, Uganda
Not Specified Eswatini, Gabon, Zimbabwe
Table 6. 
Aspects of transplantation programmes in SSA modified from Loua et al [3].
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4.4 Dearth of skilled transplant workforce
Health-workforce is the backbone of any health care system. Transplantation 
involves collaboration of many health professionals (nephrologists, transplant 
surgeons, urologists, renal nurses, pathologists, etc.). Worldwide transplant 
workforce and training capacity remain unknown. Of the 47 countries in SSA, 
only 15 (32.6%) had data on the number of nephrologists in their countries. 
Nigeria and South Africa have the greatest number of nephrologists with rates 
<10 per 10,000 population while others have < two per 10,000 population 
[3]. The situation is worse for other specialists involved in transplantation. 
Opportunities for training and employment have caused brain drain to developed 
countries from LRCs [3].
4.5 Transplant programmes
Despite the burden of ESKD in SSA, only few countries have sustained trans-
plant programmes [20]. There are only 62 centres across 7 countries in SSA [3]. 
Nigeria with a population of 206 million has 15 renal transplant centres (RTCs) 
with majority recording low activities ranging 1–5 transplants per year (Personal 
Communication). South Africa with a population of 59.37 million (2020) has 14 
RTCs and did 250 to 450 kidney transplants annually between 1991 and 2015 [35].
4.6 Shortage of organs
Scarcity of organs for transplantation is a multi-factorial global problem. Living 
donors remain the major source of organs for transplantation in SSA with largely 
non-existent deceased donor programmes. This has resulted in the persistent 
dearth of organs in the face of continuous rise in demand [92]. Unavailable stor-
age facilities, poor knowledge about transplantation, socio-cultural and religious 
beliefs (which discourage living organ donation, view deceased organ donation as 
a taboo or an act of mutilating the dead with violation of the person’s dignity [84]) 
 contribute to shortage of organs [93].
4.7 Poverty and unemployment
There is pervading poverty in SSA with US bureau of statistics reporting rates 
of 87.8%, 56.9%, 40.1%, 40% and 36.1% in Uganda, Ghana, Nigeria, Cameroun 
and Kenya respectively [94]. In Nigeria, 85% of ESKD patients earn between 
$800–7333 annually making kidney transplantation unaffordable [27, 95]. 
Although unemployment rate in SSA averages 6.2%, many are underemployed and 
earn low income [96].
4.8 Poor accessibility
Most transplant centres are located in urban cities or state capitals reducing 
accessibility to rural dwellers [3, 41].
4.9 Cultural and religious considerations
Christianity, Islam and African traditional religion are the major faiths in SSA. 
Interplay of faith, religion and cultural attitudes and their relationship with views 
on organ donation is complex. Response to illness as God’s will negates organ 
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donation or reception. Belief in resurrection and reincarnation precludes organ 
donation since the ‘new body’ may have some missing parts. Desecration of the 
body of the deceased is reported as a factor prohibiting family members from 
donating body parts of their deceased relatives.
4.10 Poor coordination and management
Functional organizational mechanism for transplant programmes including 
authorization for transplant services; ethics committees, guidelines and proto-
cols, etc. are few in the region [41, 93]. Additionally, transplant is not sufficiently 
integrated into national health services and collaboration between SSA countries is 
limited.
Absence of functional and reliable registries militate against planning and 
implementation of policies due to lack of data. Most countries do not include 
performance indicators for organ donation and transplantation in their national 
health information systems. In addition, there is insufficient multisectoral (schools, 
transport departments, NGOs, Civil Society Organizations, etc.) involvement in 
transplantation programmes in SSA.
4.11 Legal and regulatory policies
Some countries have legislation for organ donation and transplantation while 
others are in various stages of developing theirs (Table 6). The weak regula-
tory frameworks observed in these countries are often insufficient to ensure the 
effective oversight needed for the implementation of quality standards for organ 
transplantation.
4.12 Transplant tourism (TT)
The Declaration of Istanbul defines organ transplant tourism as travel for 
transplantation involving trafficking in persons, for the purpose of organ 
removal. Organ trafficking is defined as “the recruitment, transport, transfer, 
harboring, or receipt of living or deceased persons or their organs by means of any form 
of coercion, of abduction, of fraud, of deception, of the abuse of power or of a position 
of vulnerability, or of the giving to, or the receiving by, a third party of payments, or 
benefits to achieve the transfer of control over the potential donor for the purpose of 
exploitation by the removal of organs for transplantation [97].” Transplant commer-
cialism is the buying and selling of organs i.e. treating of organs as commodities. 
Travel for transplantation is the transport of organs, donors, recipients, or the 
professionals across borders for transplantation and it becomes TT if it entails 
organ trafficking and/or transplant commercialism [97]. Transplant tourism has 
become an increasing component of medical tourism (MT) especially in SSA. 
The disparity between the demand for and supply of organs encourages illegal 
organ procurement as transplantation may the only life-saving treatment in many 
end-organ failure. Unavailability and high cost of healthcare, lack of faith in local 
health systems, widening economic gap, ease of global travel and uneven global 
 application of laws, have led to increase in TT.
5. Transplant opportunities
Transplantation holds lots of opportunities which if well harnessed can improve 
healthcare in SSA.
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5.1 Availability of organs for transplantation
For sustainable transplantation programme, individuals, community and 
governmental commitment and collaboration are required. Availability of organs 
can be increased through heightened public enlightenment campaigns emphasizing 
preventive medicine and change in the community’s organ donation perception. 
This can be achieved by partnering with religious bodies, individual, family and 
community education, inclusion of transplantation and donation in school syllabus, 
alliance with the department of motor vehicles (DMV) and novel donation pro-
grammes (kidney paired donation, extended criteria organ donation and altruistic 
non-directed donation).
5.2 Comprehensive legislation and regulation
Transplantation has significant medico-legal implications requiring robust legal 
framework. This should cover organ donation legitimacy, regulatory bodies, criteria 
and processes of accreditation, certification and standardization of transplant 
centres [98]. Transplantation programmes afford SSA opportunities to learn and 
adapt legislation from other regions. In 2008, Israeli parliament accepted two laws 
from their Ministry of Health - the Brain-Respiratory Death for determination of 
brain death and the Organ transplantation laws [99]. These laws defined the ethical, 
legal and organizational aspects of organ donation, allocation and transplantation 
with prioritization of registered donors, donor reimbursement and life insurance 
[99]. These and stoppage of illegal TT reimbursement significantly increased living 
and deceased organ donation by 2011 [99, 100].
5.3 Manpower development
The Multidisciplinary nature of transplant programmes demands highly skilled 
manpower often not obtainable in many parts of SSA, hence the need for collabora-
tion with advanced transplant centres. Such patnership enables capacity develop-
ment and training of specialized workforce which will serve the local and sister 
institutions.
5.4 Transplant protocols and registry
Successful transplantation requires protocols for recipient and donor care. 
Transplant centres in LRCs can develop or adapt protocols from advanced centres, 
international organizations like United Network for Organ Sharing, Donation and 
Transplant Institute etc. National registries of organ transplant and outcomes are 
essential for documentation of transplant activities, reporting of short and long-
term outcomes, and for planning and budgeting.
5.5 Developing transplant programmes
Each country should establish a sustainable transplant programme. 
Development of such services will curb organ trafficking and TT [101]. It entails 
infrastructural, legislative and manpower development with national government’s 
political will [35, 102]. A well-defined mode of funding which includes transplanta-
tion in national health insurance coverage ensures sustainability.
Transplantation programme can be established in a staged fashion [101]: enact-
ing transplantation related laws and regulations, capacity building, extensive public 
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enlightenment campaigns and transplant beginning with live-donor and subse-
quently, deceased-donor.
5.5.1 Transplant models
Models that can be adapted include:
5.5.1.1 The Pakistani model
In the Pakistani model [103, 104], following intense public enlightenment, 
the community assumed ownership of the programme through donations as 
individuals, communities and NGOs. Government provided 30–40% of required 
cost, infrastructure, staff training and emolument enabling patients to receive 
free nephrology and transplantation care plus post-transplant rehabilitation. 
Accountability, transparency and equity ensured the success of this model.
5.5.1.2 Iranian model
Following development of indigenous transplant programme in 1985, there was 
an unwieldy transplant waiting list necessitating government-sponsored live-
unrelated transplant with donor compensation [105]. This programme successfully 
eliminated waiting list by 1999 increasing kidney transplantation to 28 pmp per 
year. The Dialysis and Transplant Patients Association facilitated donor-recipient 
matching excluding third party. Donors also received government-funded life 
health insurance and gifts. Government additionally supported importation and 
free distribution of immunosuppressive medications to recipients. Deceased donor 
transplantation has steadily increased since 2000.
These models emphasize the indispensable roles of community, government and 
NGOs in ensuring the existence of a sustainable transplantation programme.
6.  Other aspects of transplantation in sub-Saharan Africa: guidance 
efforts by international organization
The World Health Assembly (WHA) adopted resolutions WHA57.18 and 
WHA63.22 [106, 107], and the WHO guiding principles on human cell, tissue and 
organ transplantation to guide transplantation programmes and activities [108]. 
The United Nations General assembly adopted these resolutions to strengthen 
and promote effective measures and international cooperation to prevent and 
combat organ trafficking [109]. The Istanbul declaration on organ trafficking and 
TT recommends a legal and professional framework to govern organ donation 
and transplantation activities, transparent regulatory oversight system to ensure 
donor and recipient safety, enforce standards and prohibit unethical practices in all 
countries [97]. A Task Force to check unwholesome practices in transplantation was 
set up and inaugurated by WHO in 2017 [110].
During the 2013 Global Alliance of Transplantation (GAT) meeting organized 
by Southern African Transplant Society in Durban [3], the transplantation society 
(TTS) sponsored a meeting for countries in SSA to assess the need for and ability to 
optimize or develop local transplant programmes. In 2015, the South African Renal 
Society–African Association of Nephrology in collaboration with European Renal 
Association-European Dialysis and Transplant Association held a pre-congress 
workshop to encourage SSA countries to develop renal registries [111]. Attempts 
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at establishing renal registries in SSA have met with challenges. The International 
Society of Nephrology (ISN) is supporting establishment of renal registries 
worldwide through her SHARing Expertise (https://www.theisn.org/initiatives/
data-collection/). Leveraging on such programmes can help SSA countries establish 
reliable registries.
To improve kidney disease patients’ care and capacity building worldwide, ISN 
pioneers these programs: fellowship, ISN continuing medical education, sister 
renal centre (SRC), sister transplant centre (STC) and educational ambassadors 
programme. Through ISN- TTS-STC program, ISN encourages establishment and 
development of transplant centres (www.theisn.org/programs). In ISN- TTS STC 
programme, SSA centres (emerging centres) can partner with developed centres 
(supporting centre) for capacity building through institutional and exchange train-
ing programmes at no cost to the individual or his home institution. This partner-
ship is superior to the intermittent use of paid expatriates in some SSA countries.
7. Recommendations
Improvement in the transplant landscape of SSA can be achieved by adapt-
ing models that have proven successful in LRCs such as those of Pakistan and 
Iran. Implementing the 2007 World Health Organization Regional Consultation 
recommendations: establishment of national legal framework and self-sufficient 
organ donation and transplantation in each country, transparent transplantation 
practices, and prevention of commercialized transplantation and TT will improve 
transplantation programmes in SSA. Also, adopting the WHO Regional Committee 
for Africa’s proposed actions on organ transplantation for member states and estab-
lishment of national registries for organ transplantation in each country are needed.
8. Conclusion
Sub-Saharan Africa, comprising of 47 countries and occupying an area of about 
24 million Km2 is heterogeneous with estimated population of 1.1 billion people. 
Most of the countries belong to the LICs and LMICs according to World Bank 
Classification of economies. This region has a high prevalence of end-organ diseases 
including CKD, CLD, chronic lung diseases and chronic heart diseases resulting 
from CDs and NCDs.
Although South Africa performed Africa’s first kidney transplant in 1966 and 
pioneered heart transplantation in 1967, SSA lags behind the developed world 
in transplant activity. According to WHO, SSA contributes the least number of 
transplant activity per WHO World region. Cost of treatment, low GDP, inad-
equate infrastructural and institutional support, dearth of facilities and technical 
expertise and absence of subsidy have all adversely affected organ donation and 
transplantation.
The health-care systems in SSA are weak and deficient. Peoples’ decision to 
access healthcare services is influenced by knowledge of the disease condition, 
accessibility to health-care facility, affordability, religious and trado-cultural 
practices. Many people in LRCs patronize alternative healthcare service including 
traditional health providers and religious institutions as first choice resulting in late 
presentation to hospitals.
These challenges can be surmounted by adopting the 2007 World Health 
Organization Regional Consultation recommendations of establishment of national 
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legal framework, self-sufficient organ donation and transplantation in each 
country, transparent transplantation practice, and prevention of commercialized 
transplantation and TT. In addition, establishment of national registries of organ 
transplantation is essential.
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